Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Most Shorted Stocks
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Investors
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Careers
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
MCP for Agents
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Most Shorted Stocks
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Center
Investors
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
DE:ZA71
Stock Latest News
The Fly
Larimar Therapeutics price target lowered to $11 from $12 at Wedbush
24d ago
LRMR
Premium
Ratings
Larimar Therapeutics: Buy Rating Reaffirmed as FDA-Backed Nomlabofusp Progress Supports Unchanged $25 Price Target
24d ago
LRMR
Premium
Ratings
Analyst Sees Larimar as Undervalued on Nomlabofusp’s Strong Efficacy and On‑Track BLA, Reiterates Buy Rating Ahead of 2027 FA Launch
24d ago
LRMR
Premium
Company Announcements
Regulatory and Manufacturing Risks Cloud Larimar Therapeutics’ Accelerated Approval Path for Nomlabofusp
24d ago
LRMR
Premium
The Fly
Larimar Therapeutics reports Q2 EPS (30c), consensus (38c)
25d ago
LRMR
Premium
Company Announcements
Larimar reports Q2 results and nomlabofusp progress
25d ago
8K
LRMR
Premium
Pre-Earnings
Larimar Therapeutics, Inc. (LRMR) Q2 Earnings Cheat Sheet
25d ago
LRMR
Premium
Ratings
Buy Rating Reaffirmed on Growing Nomlabofusp Confidence; $25 Price Target Maintained
1M ago
LRMR
Premium
The Fly
Closing Bell Movers: Levi Strauss down 6% on earnings
2M ago
AP
AZZ
Premium
The Fly
Larimar Therapeutics director buys $167K in common stock
2M ago
LRMR
Premium
The Fly
Citizens biotech analysts hold an analyst/industry conference call
2M ago
BIIB
DSGN
Premium
The Fly
Larimar Therapeutics assumed with a Buy at H.C. Wainwright
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics price target lowered to $5 from $7 at Baird
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics selloff a buying opportunity, says Citi
2M ago
LRMR
Premium
Ratings
Larimar Therapeutics: Buy Rating on Nomlabofusp’s Robust FA Efficacy and De-Risked Regulatory Pathway
2M ago
LRMR
Premium
Ratings
Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price Target
2M ago
LRMR
Premium
The Fly
Midday Fly By: SpaceX to join Nasdaq-100, Comcast to split into two companies
2M ago
VZ
CRM
Premium
The Fly
Larimar stumbles on safety news even as BLA submission kicks off
2M ago
LRMR
Premium
Company Announcements
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval
2M ago
8K
LRMR
Premium
The Fly
Larimar Therapeutics submits first module of rolling BLA for nomlabofusp
2M ago
LRMR
Premium
Ratings
Larimar Therapeutics: Buy Rating Reaffirmed as Nomlabofusp Regulatory Catalysts and Data Updates Support Steady $14 Price Target and 280% Upside
2M ago
LRMR
Premium
The Fly
Larimar Therapeutics initiated with an Overweight at JPMorgan
3M ago
LRMR
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
